CALIBRA Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2016

Location

Hangzhou Zhejiang China

Primary Industry

Healthcare

About

Established in 2016 and based in Hangzhou, China, CALIBRA is a high-tech company that engages in researching and developing, clinical transformation and application of a new generation of biomarker material spectrum detection technology. Liu Huafen, the CEO of the company, was the global director of SCIEXLabs, the application innovation platform of the Danaher Group SCIEX. The company has more than ten ultra-high resolution and quantitative mass spectrometers for the analysis of complex matrix samples, as well as Hamilton Microlab STAR M high-throughput automated pipetting workstations and other pre-processing systems. The services provided by the company include clinical research and health management, metabolomics, Pharma CRO and environmental/toxicology. The products provided by the company include vitamin series, bile acid series, drug concentration series and other supporting reagents; chromatographic columns, pre-treatment plates, 96 microplates, 96SLE plates and other experimental consumables.

Current Investors

BioTrack Capital, Green Pine Capital Partners, Hillhouse Investment

Request a demo to show more

Primary Industry

Healthcare

Sub Industries

Diagnostic, Medical & Imaging Laboratories, Healthcare IT

Website

www.calibradx.com

Company Stage

Series C

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.